47
Participants
Start Date
December 31, 2013
Primary Completion Date
September 23, 2016
Study Completion Date
December 31, 2016
Hematopoietic Stem Cell Transplant
"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~* Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~* Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~* Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~* Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~* Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)"
Memorial Sloan-Kettering Cancer Center, New York
University of Rochester Medical Center, Rochester
Children's National Medical Center, Washington D.C.
Johns Hopkins, Baltimore
Duke University Medical Center, Durham
Children's Healthcare of Atlanta, Atlanta
University of Alabama at Birmingham, Birmingham
Midwest Children's Cancer, Milwaukee
Washington University/St. Louis Children's Hospital, St Louis
Children's Medical Center of Dallas, Dallas
Cook Children's Medical Center, Fort Worth
Baylor College of Medicine, Houston
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
Dana Farber Cancer Institute/Children's Hospital of Boston, Boston
University of Michigan Medical Center, Ann Arbor
University of North Carolina at Chapel Hill, Chapel Hill
Cincinnati Children's Hospital Medical Center, Cincinnati
Oregon Health and Science University, Portland
Fred Hutchinson Cancer Research Center, Seattle
British Columbia Children's Hosp-Vancouver, Vancouver
Hopital Sainte-Justine, Montreal
McGill University - Montreal, Montreal
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Blood and Marrow Transplant Clinical Trials Network
NETWORK
National Cancer Institute (NCI)
NIH
National Marrow Donor Program
OTHER
Medical College of Wisconsin
OTHER